Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $100K | $0.00 | — | — | — | — |
| Revenue growth | — | -100.0% | — | — | — | — |
| Operating income | -$4.79M | -$9.26M | -$2.24M | -$11.4M | -$8.23M | -$12.0M |
| Operating margin | -4788.0% | — | — | — | — | — |
| Net income | -$4.82M | -$9.30M | -$3.22M | -$13.0M | -$8.21M | -$12.0M |
| Net margin | -4822.0% | — | — | — | — | — |
| EPS (diluted) | -$1.07 | -$1.42 | -$24.95 | -$5,018.09 | -$1,545.55 | -$121.80 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$3.71M | -$8.31M | -$1.08M | -$8.99M | -$8.61M | -$10.2M |
| Capital expenditures | $2.00K | $0.00 | $3.00K | $8.00K | $0.00 | $3.00K |
| Free cash flow | -$3.71M | -$8.31M | -$1.09M | -$9.00M | -$8.61M | -$10.2M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $109K | $3.70M | $9.00K | $1.81M | $5.03M | $8.23M |
| Total assets | $955K | $8.34M | $383K | $2.96M | $5.74M | $8.67M |
| Total liabilities | $2.41M | $2.52M | $2.01M | $2.70M | $1.71M | $2.66M |
| Shareholders' equity | -$1.45M | -$4.85M | -$1.63M | $259K | $4.03M | $6.01M |
| Retained earnings | -$12.6M | -$21.9M | -$18.5M | -$31.5M | -$39.7M | -$51.7M |
| Shares (wtd avg diluted) | 4.51M | 6.54M | 129K | 2.60B | 6.55B | 98.2B |
Every figure is extracted from GRI Bio, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.